Literature DB >> 20851366

Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.

Stefano Fedele1, Stephen R Porter, Francesco D'Aiuto, Suad Aljohani, Paolo Vescovi, Maddalena Manfredi, Paolo G Arduino, Roberto Broccoletti, Anna Musciotto, Olga Di Fede, Tony S Lazarovici, Giuseppina Campisi, Naom Yarom.   

Abstract

PURPOSE: To report a case series of patients with the nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw-a form of jaw osteonecrosis that does not manifest with necrotic bone exposure/mucosal fenestration.
METHODS: Among 332 individuals referred to 5 clinical centers in Europe because of development of jawbone abnormalities after or during exposure to bisphosphonates, we identified a total of 96 patients who presented with the nonexposed variant of osteonecrosis. Relevant data were obtained via clinical notes; radiological investigations; patients' history, and referral letters.
RESULTS: The most common clinical feature of nonexposed osteonecrosis was jaw bone pain (88/96; 91.6%); followed by sinus tract (51%), bone enlargement (36.4%); and gingival swelling (17.7%). No radiological abnormalities were identified in 29.1% (28/96) of patients. In 53.1% (51/96) of the patients; nonexposed osteonecrosis subsequently evolved into frank bone exposure within 4.6 months (mean; 95% confidence interval; 3.6-5.6).
CONCLUSIONS: Clinicians should be highly vigilant to identify individuals with nonexposed osteonecrosis, as the impact on epidemiological data and clinical trial design could be potentially significant. Although the present case series represents approximately 30% of all patients with bisphosphonates-associated osteonecrosis observed at the study centers, further population-based prospective studies are needed to obtain robust epidemiological figures.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851366     DOI: 10.1016/j.amjmed.2010.04.033

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  63 in total

Review 1.  Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.

Authors:  A Khan; A Morrison; A Cheung; W Hashem; J Compston
Journal:  Osteoporos Int       Date:  2015-10-22       Impact factor: 4.507

Review 2.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

Review 3.  Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.

Authors:  Valesca Sander Koth; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2016-05-31       Impact factor: 2.419

Review 4.  Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.

Authors:  Paul de Boissieu; L Kanagaratnam; R Mahmoudi; A Morel; M Dramé; T Trenque
Journal:  Eur J Clin Pharmacol       Date:  2017-02-10       Impact factor: 2.953

5.  Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.

Authors:  Rafael Scaf de Molon; Simon Cheong; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2014-08-02       Impact factor: 4.398

Review 6.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

7.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

8.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

9.  Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis.

Authors:  Miguel Luciano Silva; Leandro Tasso; Alan Arrieira Azambuja; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Vinicius Duval da Silva; Karen Cherubini
Journal:  Clin Oral Investig       Date:  2016-03-09       Impact factor: 3.573

10.  Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw.

Authors:  Tomoya Soma; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Satoshi Nakamura; Yosuke Kaneko; Eri Ito; Hiroyuki Okada; Hisato Watanabe; Kana Miyamoto; Morio Matsumoto; Masaya Nakamura; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  J Bone Miner Metab       Date:  2020-11-17       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.